The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practice Settings in Italy

被引：0
|
作者：
Federico Spandonaro
Fabio Ayala
Enzo Berardesca
Sergio Chimenti
Giampiero Girolomoni
Patrizia Martini
Andrea Peserico
Barbara Polistena
Antonio Puglisi Guerra
Gino Antonio Vena
Gianfranco Altomare
Piergiacomo Calzavara Pinton
机构：
[1] University of Rome Tor Vergata,Department of Dermatology
[2] University of Naples Federico II,Department of Dermatology
[3] San Gallicano Dermatological Institute,Department of Medicine, Section of Dermatology and Venereology
[4] University of Rome “Tor Vergata”,Unit of Dermatology
[5] University of Verona,Unit of Dermatology, Department of Medicine
[6] Lucca Hospital,Department of Dermatology
[7] University of Padua,Department of Dermatology
[8] Messina Hospital,Department of Dermatology
[9] Dermatology and Venereology Private Practice,undefined
[10] Dermatology and Venereology Private Practice,undefined
[11] IRCCS Galeazzi Orthopedic Institute,undefined
[12] Spedali Civili,undefined
来源：
BioDrugs | 2014年 / 28卷
关键词：
Psoriasis; Infliximab; Etanercept; Adalimumab; Health Technology Assessment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：285 / 295
页数：10
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kontodimas, S.
    Kourlaba, G.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [32] COST-PER-RESPONDER FOR BIOLOGIC DRUGS USED IN THE TREATMENT OF PLAQUE PSORIASIS IN FRANCE AND GERMANY
    Skowron, F.
    Mathiasen, N.
    Schnack, H.
    Danoe, A.
    VALUE IN HEALTH, 2023, 26 (06) : S74 - S74
  • [33] A nnual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
    Fragoulakis, Vassilis
    Raptis, Efklidis
    Vitsou, Elli
    Maniadakis, Nikolaos
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 73 - 83
  • [34] Effectiveness of subcutaneous methotrexate in chronic plaque psoriasis
    Yesudian, P. D.
    Al-Niami, F.
    Balasubramanium, P.
    MacFarlane, A.
    Chalmers, R. J.
    Griffiths, C. E. M.
    Warren, R. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 65 - 65
  • [35] Ustekinumab in the therapy of chronic plaque psoriasis
    O'Neill, Jenna L.
    Kalb, Robert E.
    BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 159 - 168
  • [36] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB FOR THE TREATMENT OF ADULTS WITH MILD-TO-MODERATE PLAQUE PSORIASIS REFRACTORY TO OTHER BIOLOGIC AGENTS IN MEXICO
    Salazar, A.
    Aguirre, A.
    Flores, R.
    VALUE IN HEALTH, 2016, 19 (03) : A245 - A245
  • [37] DISCONTINUATION OF BIOLOGIC THERAPIES IN CHRONIC PLAQUE PSORIASIS: A RETROSPECTIVE COHORT
    Gulliver, Susanne
    Gulliver, Wayne
    Randell, Shane
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 27 - 28
  • [38] Adalimumab: a new alternative biologic agent for chronic plaque psoriasis
    Ormerod, Anthony D.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) : 435 - 436
  • [39] A COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB 300 MG VS CURRENT THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ITALY
    D'Ausilio, A.
    Aiello, A.
    Daniel, F.
    Graham, C.
    Roccia, A.
    Toumi, M.
    VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
  • [40] COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE UNITED KINGDOM
    Betts, K. A.
    Sundaram, M.
    Mughal, F.
    Yan, S. Y.
    Signorovitch, J.
    Wang, K.
    Wu, E. Q.
    VALUE IN HEALTH, 2013, 16 (07) : A505 - A506
12345